Updated:
hc1 Insights
Bradley Bostic's hc1 processes over 30 billion lab transactions to help health systems close care gaps and optimize spending.
hc1 Insights
Bostic started hc1 in Indianapolis in 2011, betting that the vast clinical, operational, and financial data locked in healthcare labs could be unlocked to improve system-wide economics. The firm targets hospitals, health systems, reference labs, and life sciences organizations; its website claims 450+ health system relationships and a data footprint covering more than 90 million unique patients. The product architecture is built to integrate with existing lab information systems and electronic health records rather than replacing them. The hc1 IQ platform addresses four distinct domains. Clinical IQ alerts clinicians to care gaps and flags patients at risk of deterioration. Ops IQ surfaces turnaround-time bottlenecks and staffing inefficiencies across lab operations. Source IQ benchmarks lab supply contracts against peer pricing and forecasts reagent consumption. Signal IQ analyzes referral patterns and market share data to identify revenue opportunities and client retention risks. The platform ingests structured claims records, lab results, patient profiles, and clinical histories, processing them through models trained on billions of lab transactions. The leadership page lists seven named executives, including Bostic as Chairman and CEO, Chris Brown as CFO, and Joanna Peyton as COO. In 2023, the firm acquired Accumen, a lab performance consultancy, to pair software with advisory services for health system lab transformation. The following year, hc1 launched the consolidated hc1 IQ platform, which it describes as an agentic intelligence layer purpose-built for laboratory data. The company's materials cite an average annual savings of over $1.2 million per health system from test-utilization reductions, alongside a 94% turnaround-time performance metric in deployed accounts. hc1 occupies a narrow structural space between generic healthcare analytics vendors and the proprietary data environments of large reference labs. Its technical differentiator is the concentration on laboratory source data as the organizing spine of health system intelligence, rather than claims-first or EHR-first architectures. The 2023 Accumen acquisition solidified an operating model that bundles software with on-the-ground lab consulting, giving the firm a services-means-of-distribution not available to pure SaaS competitors. Bostic remains the controlling operator with no outside CEO brought in since founding, suggesting governance continuity atypical of venture-backed health-tech peers at comparable maturity.
General information
Firm type
Asset Manager
Year founded
2011
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Indianapolis
Corporate office
Indianapolis, IN, United States
Principals
Bradley Bostic
Chairman and CEO
Sector focus
Frequently asked questions
Who runs investment decisions at hc1?
hc1 is a growth-stage operating company, not an investment firm — it does not deploy capital into portfolio companies or manage third-party funds. The firm provides an AI-powered lab intelligence platform to health systems. Bradley Bostic is Chairman and CEO, and strategic decisions are made by the leadership team listed on the company's website.
How does hc1's platform integrate with existing hospital systems?
hc1 IQ connects to laboratory information systems, electronic health records, and supply chain platforms through APIs, without requiring a rip-and-replace of existing infrastructure. The firm's stated design principle is to overlay its agentic intelligence onto data the lab already generates, processing that data continuously to surface prioritized alerts and workflow recommendations.
Is hc1 structured as a family office or does it operate more like a venture-backed company?
hc1 operates as a standalone enterprise selling software and advisory services to healthcare organizations. It is not a family office and, based on publicly available information, does not appear to manage a fund of outside capital. The firm's revenue comes from licensing its hc1 IQ platform and delivering consulting engagements to health systems.
What measurable outcomes does hc1 claim for its health system clients?
The firm's website references average annual savings exceeding $1.2 million per health system, a 20% reduction in unnecessary testing, and a 40% faster time to clinical intervention. It also touts a case study in which a regional health system identified over $1.2 million in unnecessary testing within 90 days of deployment. The 94% turnaround time performance metric is cited as an operational benchmark in active accounts.
How is hc1's product suite organized?
The hc1 IQ platform consists of four modules. Clinical IQ identifies at-risk patients and care gaps. Ops IQ provides real-time visibility into lab turnaround times and workflow bottlenecks. Source IQ benchmarks supply contracts and forecasts reagent needs. Signal IQ analyzes market share, referral patterns, and client churn risk for lab outreach teams.
What was the strategic rationale behind acquiring Accumen?
In 2023, hc1 acquired Accumen, a consulting firm focused on lab performance optimization. The deal added deep consulting expertise that complements the software platform, allowing hc1 to offer health systems an integrated combination of technology and advisory services for lab transformation. The firm described the acquisition as completing an end-to-end partner for lab performance.
What is the firm's posture on scaling beyond lab data?
hc1's positioning emphasizes laboratory data as a central organizing layer for health system intelligence, deliberately distinct from broader analytics platforms built primarily on claims or EHR data. The firm does not market its product as a general-purpose healthcare analytics tool, and its language focuses on activating the diagnostic and operational signals specific to the lab domain.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: